Showing 9201-9210 of 10267 results for "".
- Pliaglis Launches in Europehttps://practicaldermatology.com/news/20130502-pliaglis_launches_in_europe/2459551/Nuvo Research Inc. and Galderma Pharma, S.A. launched Pliaglis (lidocaine and tetracaine) Cream 7%/7% in Europe. Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, and licenses have been issued in 14 of the 16 European cou
- Lambrolizumab Designated as Breakthrough Therapyhttps://practicaldermatology.com/news/20130429-lambrolizumab_designated_as_breakthrough_therapy/2459556/Merck & Co. received breakthrough therapy designation from the US Food and Drug Administration for its lambrolizumab drug as a treatment of patients with advanced melanoma. Lambrolizumab is Merck's investigational antibody therapy targeting Programm
- Dermatology Partnerships Exploredhttps://practicaldermatology.com/news/20121115-dermatology_partnerships_explored/2459681/Research and Markets has added the "Dermatology Partnering Terms and Agreements" report to their offering. This report provides a detailed understanding and analysis of how and why companies enter dermatology
- Pharma Penalties Total $10.2B Over Two Yearshttps://practicaldermatology.com/news/20120928-pharma_penalties_total_102b_over_two_years/2459727/Pharmaceutical manufacturers have reached a total of 74 settlements, totaling $10.2 billion in financial penalties with federal and state governments between November 2, 2010 and July 18, 2012. That's the conclusion of an updated report from P
- p53R2 Regulates Proliferation and Chemosensitivity in Melanomahttps://practicaldermatology.com/news/20120918-p53r2_regulates_proliferation_and_chemosensitivity_in_melanoma/2459734/Expression of p53R2 significantly correlates with the depth of invasion and the tumor stage in melanoma, new research shows. (J Dermatol Sci; 68(1):19-24) Furthermore, use of siRNA targeting p53R2 successfully knocked down p53R2 and significantly inhibited the growth of KHm5 and 6 cells. The degree
- CMS Provider Call Today on EHRshttps://practicaldermatology.com/news/20120913-cms_provider_call_today_on_ehrs/2459740/The Centers for Medicare and Medicaid Services will host a 90-minute National Provider Call today, Sept. 13, to discuss the final rule for the Stage 2 electronic health records meaningful use program. The call is free, but prior registration is required.
- Galderma's Cetaphil Celebrates 65 Yearshttps://practicaldermatology.com/news/20120711-galdermas_cetaphil_celebarates_65_years/2459775/Galderma's Cetaphil Gentle Skin Cleanser is celebrating 65 years on the market. Introduced in 1947 as Cetaphil Cleansing Lotion, it was initially developed by a pharmacist for use as a compounding base. By the 1960s, the product was so popular t
- Provectus Pharmaceuticals Presents Phase II Data on PV-10https://practicaldermatology.com/news/20120627-provectus_pharmaceuticals_presents_phase_ii_data_on_pv-10/2459780/Provectus Pharmaceuticals, Inc. (OTCBB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, presented its top-line final data from the Phase II clinical trial of PV-10 for metastatic melanoma. Results were showcased at the
- Psoriasis Genetic Map Explored by International Psoriasis Councilhttps://practicaldermatology.com/news/20120607-psoriasis_genetic_map_explored_by_international_psoriasis_council/2459788/The International Psoriasis Council (IPC) is leading the effort to establish collaboration among leading geneticists and dermatologists to advance the understanding of the genetic basis of psoriasis. Their
- Provectus Pharmaceuticals' PV-10 Phase 2 Final Data To Be Presentedhttps://practicaldermatology.com/news/20120509-provectus_pharmaceuticals_pv-10_phase_2_final_data_to_be_presented/2459806/Phase 2 final data on PV-10 for metastatic melanoma by Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) will be presented at the second European PostASCO Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanom